Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation

European Heart Journal

Volumn 27, Issue 2, 2006, Pages 166-170

  Hofma, Sjoerd H ^a   Van Der Giessen, Wim J ^a   Van Dalen, Bas M ^a   Lemos, Pedro A ^a   McFadden, Eugene P ^a   Sianos, Georgios ^a   Ligthart, Jurgen M R ^a   Van Essen, Dirk ^a   De Feyter, Pim J ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coronary stents; Drugs; Endothelium

Indexed keywords

ACETYLCHOLINE; NITRATE; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; EPICARDIUM; FEMALE; FOLLOW UP; HUMAN; INTRACORONARY INFUSION; INTRAVASCULAR ULTRASOUND; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX;

AGED; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VASOSPASM; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NITROGLYCERIN; PROSPECTIVE STUDIES; SIROLIMUS; STENTS; VASODILATION; VASODILATOR AGENTS;

EID: 30344439818     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi571     Document Type: Article

References (17)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Cater AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
4. van Beusekom HM, Whelan D, Hofma SH, Krabbendam SC, van Hinsbergh VWM, Verdouw PD, Van der Giessen WJ. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J Am CollCardiol 1998;32:1109-1117.
5. Caramori PRA, Lima VC, Seidelin PH, Newton GE, Parker JD, Adelman AG. Long-term endothelial dysfunction after coronary artery stenting. J Am Coll Cardiol 1999;34:1675-1679.
6. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-236.
7. Finkelstein A, McClean D, Kar S, Takizawa K, Varghese K, Baek N, Park K, Fishbein MC, Makkar R, Litvack F, Eigler NL. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003;107:777-784.
8. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051.
9. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-2651.
10. Gössl M, Rosol M, Malyar NM, Fitzpatrick LA, Beighley PE, Zamir M, Ritman EL. Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. Anat Rec Part A 2003;272:526-537.
11. Corbin F, Blaise GA, Parent M, Chen H, Daloze PM. Effect of rapamycin on rat aortic ring vasomotion. J Cardiovasc Pharm 1994;24:813-817.
12. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault LP. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002;21:990-998.
13. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine 2002;8:128-135.
14. Morice M-C, Serruys P, Constantini C, Wuelfert E, Wijns W, Fajadet J, Colombo A, Guagliumi G, Molnar F, Hayashi EB, Sousa JE, Perin M; The RAVEL trial Investigators. Three-year follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions. J Am Coll Cardiol 2004;43:87A.
15. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
16. Sabate M, Kay P, van der Giessen WJ, Cequier A, Ligthart JMR, Gomez-Hospital JA, Carlier SG, Coen VLMA, Marijnissen JPA, Wardeh AJ, Levendag PC, Serruys PW. Functional assessment of coronary arteries previously treated with angioplasty and intracoronary radiation. Circulation 1999;100:1623-1629.
17. Treasure CB, Klein JL, Weintraub WS, Talley D, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.